One placement.28 days of therapy at the tumor bed.
MediChip™ is a biodegradable, 3D-printed implant placed directly at the tumor bed. It delivers sustained cytotoxic therapy locally over 28 days from a single placement, without systemic exposure.
Why Localized Delivery?
Cytotoxic agents are dosed to what the whole body can tolerate, not to what the tumor requires. Toxicity to healthy tissue sets the ceiling.
Delivering therapy directly at the tumor bed decouples local concentration from systemic exposure — sustained release over weeks from a single placement.
The delivery architecture is not specific to one drug. It is designed to carry a range of therapeutic payloads across solid tumor indications.
Cancer treatment shouldn't require treating the entire body.
Systemic administration caps the deliverable dose at whole-body tolerance. MediChip™ decouples local concentration from systemic exposure — sustained release at the tumor bed from a single placement, no repeat administration.
Local Delivery
Sustained Release
Agent-Agnostic Architecture
.jpg)
Help shape the future of localizedcancer therapy.
Whether you're a pharmaceutical company, research institution, clinical investigator, or strategic partner, we're building the next generation of localized oncology treatments together.
.avif)